Brigatinib: First Global Approval

<div>Compliance with Ethical Standards</div><div><br></div><div><i>Funding:</i> The preparation of this review was not supported by any external funding. </div><div><br></div><div><i>Conflict of Interest:</i> A. Markham is a contracted employee of Adis, Springer SBM.</div><div><br></div><div>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.</b></div><div><br></div><div>Abstract</div><div><br></div><div>Brigatinib (Alunbrig™) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals. In April 2017 brigatinib was approved in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to the latter is a therapeutic challenge which has led to the development of second-generation ALK-inhibitors such as brigatinib which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. Access to the full article can be found <b><a href="https://link.springer.com/article/10.1007/s40265-017-0776-3">here</a>.</b></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017